Reduced uterine perfusion pressure induces hypertension in the pregnant mouse

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 307, Issue 11, 2014, Pages R1353-R1357

  Intapad, Suttira ^a   Warrington, Junie P ^a   Spradley, Frank T ^a   Palei, Ana C ^a   Drummond, Heather A ^a   Ryan, Michael J ^a   Granger, Joey P ^a   Alexander, Barbara T ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Hypertension; Intrauterine growth restriction; Mouse; Placental ischemia; Pregnancy

Indexed keywords

PROTEIN TYROSINE KINASE; SOLUBLE FMS RELATED TYROSINE KINASE 1; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY; ARTERY BLOOD FLOW; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FETUS WEIGHT; GESTATIONAL AGE; INTRAUTERINE PRESSURE; ISCHEMIA; MATERNAL HYPERTENSION; MEAN ARTERIAL PRESSURE; MOUSE; MOUSE MODEL; NEWBORN; NONHUMAN; OVARIAN ARTERY; PERFUSION PRESSURE; PLACENTA INSUFFICIENCY; PLACENTA WEIGHT; PLACENTAL ISCHEMIA; PREGNANCY; REDUCED UTERINE PERFUSION PRESSURE; ANIMAL; BIRTH WEIGHT; BLOOD FLOW; BLOOD PRESSURE; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PERFUSION; PHYSIOLOGY; PLACENTA; PROTEINURIA; UTERUS; VASCULARIZATION;

ANIMALS; BIRTH WEIGHT; BLOOD PRESSURE; BODY WEIGHT; FEMALE; HYPERTENSION, PREGNANCY-INDUCED; MICE; ORGAN SIZE; PERFUSION; PLACENTA; PLACENTAL INSUFFICIENCY; PREGNANCY; PROTEINURIA; REGIONAL BLOOD FLOW; UTERUS;

EID: 84914164724     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00268.2014     Document Type: Article

References (30)

1. Alexander BT. Placental insufficiency leads to development of hypertension in growth-restricted offspring. Hypertension 41: 457–462, 2003.
2. Alexander BT, Kassab SE, Miller MT, Abram SR, Reckelhoff JF, Bennett WA, Granger JP. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 37: 1191–1195, 2001.
3. American College of Obstetricians, and Gynecologists and Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122: 1122–1131, 2013.
4. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves ACh, Gröne HJ, Ahmed A, Weich HA. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 14: 1857–1867, 2010.
5. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ, Granger JP. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 22: 564–568, 2009.
6. Ducray JF, Naicker T, Moodley J. Pilot study of comparative placental morphometry in pre-eclamptic and normotensive pregnancies suggests possible maladaptations of the fetal component of the placenta. Eur J Obstet Gynecol Reprod Biol 156: 29–34, 2011.
7. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50: 1142–1147, 2007.
8. Gilbert JS, Bauer AJ, Gingery A, Banek CT, Chasson S. Circulating and utero-placental adaptations to chronic placental ischemia in the rat. Placenta 33: 100–105, 2012.
9. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 55: 380–385, 2010.
10. Granger JP, LaMarca BB, Cockrell K, Sedeek M, Balzi C, Chandler D, Bennett W. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 122: 383–392, 2006.
11. Kharfi A, Giguère Y, Sapin V, Massé J, Dastugue B, Forest JC. Trophoblastic remodeling in normal and preeclamptic pregnancies: implication of cytokines. Clin Biochem 36: 323–331, 2003.
12. Kuo VS, Koumantakis G, Gallery ED. Proteinuria and its assessment in normal and hypertensive pregnancy. Am J Obstet Gynecol 167: 723–728, 1992.
13. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension 46: 1022–1025, 2005.
14. Lanoix D, St-Pierre J, Lacasse AA, Viau M, Lafond J, Vaillancourt C. Stability of reference proteins in human placenta: general protein stains are the benchmark. Placenta 33: 151–156, 2012.
15. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672–683, 2004.
16. Li F, Hagaman JR, Kim HS, Maeda N, Jennette JC, Faber JE, Karumanchi SA, Smithies O, Takahashi N. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like pheno-type. J Am Soc Nephrol 23: 652–660, 2012.
17. Li J, LaMarca B, Reckelhoff JF. A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. Am J Physiol Heart Circ Physiol 303: H1–H8, 2012.
18. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, Hankins GD, Saade GR. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 196: 396. e1–e7, 2007.
19. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 71: 977–984, 2007.
20. Morgan T, Craven C, Ward K. Human spiral artery renin-angiotensin system. Hypertension 32: 683–687, 1998.
21. Murphy SR, LaMarca B, Cockrell K, Arany M, Granger JP. L-argi-nine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. Am J Physiol Regul Integr Comp Physiol 302: R259–R263, 2012.
22. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 55: 394–398, 2010.
23. Page EW, Christianson R. Influence of blood pressure changes with and without proteinuria upon outcome of pregnancy. Am J Obstet Gynecol 126: 821–833, 1976.
24. Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf) 208: 224–233, 2013.
25. Payne JA, Alexander BT, Khalil RA. Reduced endothelial vascular relaxation in growth-restricted offspring of pregnant rats with reduced uterine perfusion. Hypertension 42: 768–774, 2003.
26. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental expression of vascular endothelial growth factor recep-tor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26: 563–573, 2005.
27. Sadovsky E, Aboulafia Y, Milwidsky A, Weinstein D, Polishuk WZ. Preeclampsia and fetal well-being. Isr J Med Sci 12: 528–533, 1976.
28. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102: 1566–1574, 2008.
29. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 365: 785–799, 2005.
30. Wheeler TL, Blackhurst DW, Dellinger EH, Ramsey PS. Usage of spot urine protein to creatinine ratios in the evaluation of preeclampsia. Am J Obstet Gynecol 196: 465, e461–e464, 2007.